NCT01693653View on ClinicalTrials.gov

Tocilizumab for the Treatment of Behcet's Syndrome

PHASE2TerminatedINTERVENTIONAL

Enrollment

1

Participants

Timeline

Start Date

September 30, 2012

Primary Completion Date

November 30, 2013

Study Completion Date

November 30, 2013

Conditions

Behcet Syndrome

Interventions

DRUG

Tocilizumab

Intravenous infusions every 4 weeks for 3 doses.

Trial Locations (1)

10016

NYU Center for Musculoskeletal Care, New York

Sponsors

Collaborators (1)

Genentech, Inc.

All Listed Sponsors

collaborator

Genentech, Inc.

INDUSTRY

lead

NYU Langone Health

OTHER